10-Q: Novanta Q2 2025: Mixed Results Amid Restructuring

Novanta Inc. reports a 2.2% revenue increase for Q2 2025, driven by acquisitions and Automation Enabling Technologies, but operating income and EPS declined due to higher restructuring and acquisition costs.

Summary

• Total revenue for the three months ended June 27, 2025, was $241.0 million, an increase of 2.2% from the prior year period.
• Total revenue for the six months ended June 27, 2025, was $474.4 million, an increase of 1.6% from the prior year period.
• Acquisition activities contributed $5.3 million to revenue for both the three and six months ended June 27, 2025.
• Foreign currency exchange rates favorably impacted revenue by $4.8 million (2.0%) for the three months and $3.3 million (0.7%) for the six months ended June 27, 2025.
• Operating income for the three months ended June 27, 2025, decreased by $10.8 million, or 42.0%, to $14.9 million.
• Operating income for the six months ended June 27, 2025, decreased by $4.0 million, or 7.8%, to $47.3 million.
• Basic and Diluted Earnings Per Share (EPS) for the three months ended June 27, 2025, was $0.12, a decrease of $0.26 from the prior year period.
• Basic and Diluted EPS for the six months ended June 27, 2025, was $0.71, a decrease of $0.08 from the prior year period.
• Automation Enabling Technologies segment revenue increased by 4.2% in the three months and 4.6% in the six months ended June 27, 2025, primarily due to increased demand in robotics and automation products.
• Medical Solutions segment revenue increased by 0.2% in the three months but decreased by 1.3% in the six months ended June 27, 2025, with acquisition contributions partially offset by lower precision medicine product sales.
• Gross profit margin improved to 44.3% for the three months and 44.5% for the six months ended June 27, 2025.
• Restructuring, acquisition, and related costs increased to $12.6 million for the three months and $10.1 million for the six months ended June 27, 2025.
• Net interest expense decreased due to lower average debt levels and a lower weighted average interest rate (5.35% for Q2 2025 vs. 6.74% for Q2 2024).
• Foreign exchange transaction losses increased to $2.7 million for the three months and $3.1 million for the six months ended June 27, 2025.
• Effective tax rate for the three months ended June 27, 2025, was 22.3% (vs. 19.7% prior year) and 20.2% for the six months (vs. 16.5% prior year).
• Acquired Keonn Technologies, S.L. on April 8, 2025, for an estimated total purchase consideration of $75.4 million, including $4.5 million in estimated contingent consideration.
• Entered into a Fourth Amended and Restated Credit Agreement on June 27, 2025, for approximately $1.0 billion, maturing in June 2030, with an uncommitted accordion feature of $350.0 million.
• Repurchased 46 thousand common shares for $6.2 million under the 2020 Repurchase Plan, with $43.3 million remaining available.
• Initiated a 2025 restructuring program with expected total charges ranging from $20.0 million to $25.0 million, anticipated to be substantially completed by the end of 2026.

Sentiment

Score: 4

Explanation: While Novanta Inc. achieved revenue growth and improved gross margins, the significant decline in operating income and net income, coupled with increased restructuring and acquisition-related costs, indicates a challenging period. The strategic acquisitions and credit facility refinancing are positive long-term moves, but current profitability is negatively impacted by integration and restructuring efforts, and operating cash flow decreased.

Positives

• Total revenue increased by 2.2% for the three months and 1.6% for the six months ended June 27, 2025.
• The acquisition of Keonn Technologies contributed $5.3 million to revenue in the current year period.
• Automation Enabling Technologies segment showed strong revenue growth of 4.2% in Q2 and 4.6% in H1, driven by increased demand in robotics and automation products.
• Gross profit margins improved across both segments and overall, reaching 44.3% in Q2 and 44.5% in H1.
• Net interest expense decreased due to lower average debt levels and a reduced weighted average interest rate (5.35% in Q2 2025 vs. 6.74% in Q2 2024).
• Successfully refinanced credit facilities with a new $1.0 billion agreement maturing in June 2030, providing long-term financial flexibility.
• The new credit agreement includes an uncommitted accordion feature for an additional $350.0 million in aggregate commitments.
• Maintained compliance with all financial covenants under the Senior Credit Facilities as of June 27, 2025.
• Continued share repurchases under the 2020 Repurchase Plan, returning capital to shareholders.

Negatives

• Operating income significantly decreased by 42.0% for the three months and 7.8% for the six months ended June 27, 2025.
• Net income and Earnings Per Share (EPS) declined substantially for both the three and six months ended June 27, 2025.
• Medical Solutions segment revenue decreased by 1.3% for the six months ended June 27, 2025, primarily due to lower precision medicine product sales.
• Restructuring, acquisition, and related costs increased significantly, impacting profitability.
• Selling, General and Administrative (SG&A) expenses increased due to costs associated with the planning and design phase of an enterprise resource planning (ERP) system implementation.
• Research and Development (R&D) expenses increased.
• Experienced increased foreign exchange transaction losses.
• The effective tax rate increased compared to prior year periods.
• Cash provided by operating activities decreased from $73.9 million in H1 2024 to $46.8 million in H1 2025, primarily due to increased inventory and higher cash paid for income taxes.

Risks

• Economic and political conditions, including supply chain disruptions, labor shortages, market volatility, and new tariffs, could adversely affect customer businesses, capital expenditures, and business activities.
• Dependence on the ability to respond to fluctuations in product demand.
• Ability to continuously innovate, introduce new products in a timely manner, and manage transitions to new product innovations effectively.
• Disruptions or breaches in security of information technology systems.
• Risks associated with operations in foreign countries and increased use of outsourcing.
• Exposure to increased tariffs, trade restrictions, or taxes on products.
• Ability to contain or reduce costs.
• Violations of intellectual property rights and the ability to protect intellectual property against infringement by third parties.
• Risk of losing competitive advantage.
• Failure to successfully integrate recent and future acquisitions into the business.
• Ability to attract and retain key personnel.
• Product defects or problems integrating products with other vendors' products.
• Disruptions in the supply of certain key components and other goods from suppliers.
• Failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments.
• Production difficulties and product delivery delays or disruptions.
• Exposure to extensive medical device regulations, which may impede or hinder product approval, certification, or sale.
• Potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations.
• Impact of healthcare industry cost containment and healthcare reform measures.
• Changes in governmental regulations related to the business or products.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws, regulations, standards, and other requirements.
• Failure to implement new information technology systems successfully.
• Changes in foreign currency rates.
• Failure to realize the full value of intangible assets.
• Reliance on original equipment manufacturer (OEM) customers.
• Loss of sales, or significant reduction in orders from, any major customers.
• Increasing scrutiny and changing expectations from investors, customers, governments, and other stakeholders with respect to corporate sustainability policies and practices.
• The effects of climate change and related regulatory responses.
• Exposure to the credit risk of some customers and in weakened markets.
• Being subject to U.S. federal income taxation even though incorporated as a non-U.S. corporation.
• Changes in tax laws and fluctuations in effective tax rates.
• Any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance existing indebtedness, which may not be available on acceptable terms or at all.
• Existing indebtedness limiting the ability to engage in certain activities.
• Volatility in the market price for common shares.
• Failure to maintain appropriate internal controls in the future.

Future Outlook

The company's strategy is to drive sustainable, profitable growth by focusing on long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets. This includes increasing medical sales through new product introductions and deepening key account relationships, as well as penetrating high-growth advanced industrial applications. The company plans to broaden its technology portfolio through increased investment in new product development and complementary acquisitions, expand sales and marketing channels, and improve operations through lean manufacturing and strategic sourcing. The 2025 restructuring program is expected to be substantially completed by the end of 2026, with total charges estimated between $20.0 million and $25.0 million. The 2024 restructuring program is anticipated to be substantially completed by the end of 2025, with additional charges of $1.5 million to $2.5 million. Capital expenditures for 2025 are projected to be between $15 million and $20 million. The company is currently assessing the impact of the recently enacted U.S. H.R.1 One Big Beautiful Bill Act on its consolidated financial statements.

Management Comments

• Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives.
• We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months.
• We continue to closely monitor the progression of legislative activities [regarding Pillar Two global minimum tax].
• We are currently assessing its impact [H.R.1 One Big Beautiful Bill Act] on our consolidated financial statements.

Industry Context

The company operates in the medical and advanced industrial markets, serving OEM customers. The medical market is influenced by hospital, life science, and healthcare provider capital spending, surgical procedure growth rates, regulatory changes, and technology demand. The advanced industrial market is affected by changing technology requirements, productivity investments, and general economic conditions, with the Purchasing Managers Index (PMI) serving as an indicator. The global economy has faced significant challenges, including inflation, supply chain disruptions, labor shortages, and market volatility, with new and proposed tariffs introducing additional uncertainty. While improvements in supply chain and talent shortages have been noted, overall macroeconomic uncertainty persists due to geopolitical tensions and changes in trade policies.

Corporate Governance

Legal Proceedings

• Subject to various legal proceedings and claims that arise in the ordinary course of business.
• Management does not believe that the outcome of outstanding claims will have a material adverse effect on financial condition or results of operations, but no assurance can be given that such claims would not have a material adverse effect.

Stakeholder Impact

• Shareholders are impacted by declining EPS and share repurchases, with potential for future growth from strategic initiatives and acquisitions.
• Employees are affected by restructuring programs, which include severance charges and streamlining management structures.
• Customers (OEMs) may benefit from new product introductions, expanded offerings, and improved customer satisfaction through lean manufacturing, but could face price increases due to inflationary conditions and tariffs.
• Suppliers are impacted by strategic sourcing initiatives and potential supply chain disruptions.
• Creditors have debt obligations secured by company assets, with a new credit agreement providing stability until June 2030.

Next Steps

• Substantially complete the 2024 restructuring program by the end of 2025, with expected additional charges of $1.5 million to $2.5 million.
• Substantially complete the 2025 restructuring program by the end of 2026, with expected total charges ranging from $20.0 million to $25.0 million.
• Continue assessing the impact of the U.S. H.R.1 One Big Beautiful Bill Act on consolidated financial statements.
• Begin quarterly principal payments on Euro Term Loans in September 2025.
• Begin quarterly principal payments on U.S. Term Loans in September 2026, increasing in September 2027.
• Continue to execute the strategy for sustainable, profitable growth, including new product introductions, deepening customer relationships, and operational improvements.

Key Dates

Recommendation

While Novanta Inc. demonstrates revenue growth and improved gross margins, the significant decline in operating income and EPS due to substantial restructuring and acquisition-related costs raises concerns about short-term profitability. The strategic acquisitions and credit facility refinancing are positive long-term moves, indicating a commitment to growth and financial stability. However, the current operational challenges, including increased expenses and reduced operating cash flow, suggest a period of integration and investment. A 'Hold' recommendation is appropriate as the company navigates these transitional challenges, with potential for future upside once restructuring benefits materialize and profitability stabilizes.

Keywords

Novanta, NOVT, Quarterly Report, Financial Results, Revenue, Operating Income, EPS, Acquisition, Keonn Technologies, RFID, Restructuring, Credit Facility, Debt, Automation Enabling Technologies, Medical Solutions, Precision Manufacturing, Robotics, Automation, Advanced Surgery, Precision Medicine, OEM, Supply Chain, Tariffs, ERP System, Corporate Governance, Risk Management